Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-akt pathway

Nutrition and Cancer

Volumn 65, Issue 7, 2013, Pages 1059-1066

  Pozsgai, Eva ^a   Bellyei, Szabolcs ^a   Cseh, Anna ^a   Boronkai, Arpad ^a   Racz, Boglarka ^a   Szabo, Aliz ^a   Sumegi, Balazs ^a   Hocsak, Eniko ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUERCETIN; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ASSAY; CELL VIABILITY; CHEMORADIOTHERAPY; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MULTIMODALITY CANCER THERAPY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMORADIOTHERAPY; DACARBAZINE; GLIOBLASTOMA; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; SIGNAL TRANSDUCTION;

EID: 84888309465     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.810291     Document Type: Article

References (35)

1. Nishikawa R: Standard therapy for glioblastoma-a review of where we are. Neurol Med Chir (Tokyo) 50, 713-719, 2010.
2. Amelio D, Lorentini S, Schwarz M, and Amichetti M: Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. Radiother Oncol 97, 361-369, 2010.
3. Bidros DS and Vogelbaum MA: Novel drug delivery strategies in neurooncology. Neurotherapeutics 6, 539-546, 2009.
4. Pozsgai E, Gomori E, Szigeti A, Boronkai A, Gallyas F, Jr., et al.: Correlation between the progressive cytoplasmic expression of a novel small heat shock protein (Hsp16.2) and malignancy in brain tumors. BMC Cancer 7, 233, 2007.
5. Balmaceda C: Advances in brain tumor chemosensitivity. Curr Opin Oncol 10, 194-200, 1998.
6. Murakami A, Ashida H, and Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett 269, 315-325, 2008.
7. Ranelletti FO, Maggiano N, Serra FG, Ricci R, Larocca LM, et al.: Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer 85, 438-445, 2000.
8. Tang SN, Singh C, Nall D, Meeker D, Shankar S, et al.: The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 5, 14, 2010.
9. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, et al.: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2, 659-668, 1996.
10. Jakubowicz-Gil J, Langner E, and Rzeski W: Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. Pharmacol Rep 63, 403-416, 2011.
11. Park MH and Min do S: Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells. Biochem Biophys Res Commun 412, 710-715, 2011.
12. Jakubowicz-Gil J, Langner E, Wertel I, Piersiak T, and Rzeski W: Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. Chem Biol Interact 188, 190-203, 2010.
13. de Boer VC, Dihal AA, van der Woude H, Arts IC, Wolffram S, et al.: Tissue distribution of quercetin in rats and pigs. J Nutr 135, 1718-1725, 2005.
14. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cyto-toxicity assays. J Immunol Methods 65, 55-63, 1983.
15. Vermes I, Haanen C, Steffens-Nakken H, and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184, 39-51, 1995.
16. Chou CC, Yang JS, Lu HF, Ip SW, Lo C, et al.: Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. Arch Pharm Res 33, 1181-1191, 2010.
17. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, et al.: Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011, 591356, 2011.
18. Staedler D, Idrizi E, Kenzaoui BH, and Juillerat-Jeanneret L: Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 68, 1161-1172, 2011.
19. Xavier CP, Lima CF, Rohde M, and Pereira-Wilson C: Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol 68, 1449-1457, 2011.
20. Thangasamy T, Sittadjody S, Mitchell GC, Mendoza EE, Radhakrishnan VM, et al.: Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer 10, 282, 2010.
21. Jeong JH, An JY, Kwon YT, Rhee JG, and Lee YJ: Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J Cell Biochem 106, 73-82, 2009.
22. Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R, et al.: Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol 11, 63-69, 2004.
23. Vargas AJ and Burd R: Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev 68, 418-428, 2010.
24. Plati J, Bucur O, and Khosravi-Far R: Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 104, 1124-1149, 2008.
25. Zamin LL, Filippi-Chiela EC, Dillenburg-Pilla P, Horn F, Salbego C, et al.: Resveratrol and quercetin cooperate to induce senescence-like growth arrest in C6 rat glioma cells. Cancer Sci 100, 1655-1662, 2009.
26. Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, et al.: Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem 280, 35767-35775, 2005.
27. Xie X, Yin J, Jia Q, Wang J, Zou C, et al.: Quercetin induces apoptosis in the methotrexate-resistant osteosarcoma cell line U2-OS/MTX300 via mitochondrial dysfunction and dephosphorylation of Akt. Oncol Rep 26, 687-693, 2011.
28. Lee YK and Park OJ: Regulation of mutual inhibitory activities between AMPK and Akt with quercetin in MCF-7 breast cancer cells. Oncol Rep 24, 1493-1497, 2010.
29. Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, et al.: Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci 102, 1822-1828, 2011.
30. Zhang HP, Takayama K, Su B, Jiao XD, Li R, et al.: Effect of sunitinib combined with ionizing radiation on endothelial cells. J Radiat Res (Tokyo) 52, 1-8, 2011.
31. Kim YH, Lee DH, Jeong JH, Guo ZS, and Lee YJ: Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 75, 1946-1958, 2008.
32. Russo M, Spagnuolo C, Tedesco I, Bilotto S, and Russo GL: The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol 83, 6-15, 2012.
33. Lee YK, Hwang JT, Kwon DY, Surh YJ, and Park OJ: Induction of apoptosis by quercetin is mediated through AMPKalpha1/ASK1/p38 pathway. Cancer Lett 292, 228-236, 2010.
34. Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, et al.: Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281, 162-170, 2009.
35. Ding M, Zhao J, Bowman L, Lu Y, and Shi X: Inhibition of AP-1 and MAPK signaling and activation of Nrf2/ARE pathway by quercitrin. Int J Oncol 36, 59-67, 2010.